ArticleJournal of medical ethics2025
Patient data for commercial companies? An ethical framework for sharing patients' data with for-profit companies for research.
Article in Journal of medical ethics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 15 citations in OpenAlex.
- Reclaiming Data, Restoring Health: The Indigenous Biomedical Data Science Renaissance.Annual review of biomedical data science · 2026Review
- High Patient Willingness to Grant Broad Consent for Real-World Data Use in Rheumatology-Implications for Real-World Data Platform Governance: Cross-Sectional Study.Journal of medical Internet research · 2026Article
- Anticipating Moral and Economic Considerations, Opportunities, and Potential Frictions for AI in Medical Imaging: Multistakeholder Cocreation Study.Journal of medical Internet research · 2026Article
- Unlocking insights: general practice staff perspectives on sharing general practice data for research - a scoping review.BMC primary care · 2025Article
- A scoping review of ethical aspects of public-private partnerships in digital health.NPJ digital medicine · 2025Article
- Self-monitoring of health - user viewpoints on gathering data using consumer health technologies during leisure time.Frontiers in digital health · 2025Article
- What Do We Mean by Sharing of Patient Data? DaSH: A Data Sharing Hierarchy of Privacy and Ethical Challenges.Applied clinical informatics · 2024Article
- Promoting Data Sharing: The Moral Obligations of Public Funding Agencies.Science and engineering ethics · 2024Article
- Ethical and social implications of public-private partnerships in the context of genomic/big health data collection.European journal of human genetics : EJHG · 2024Article
- UNCAN.eu: Toward a European Federated Cancer Research Data Hub.Cancer discovery · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundResearch using data from medical care promises to advance medical science and improve healthcare. Academia is not the only sector that expects such research to be of great benefit. The research-based health industry is also interested in so-called 'real-world' health data to develop new drugs, medical technologies or data-based health applications. While access to medical data is handled very differently in different countries, and some empirical data suggest people are uncomfortable with the idea of companies accessing health information, this paper aims to advance the ethical debate about secondary use of medical data generated in the public healthcare sector by for-profit companies for medical research (ReuseForPro).
methodsWe first clarify some basic concepts and our ethical-normative approach, then discuss and ethically evaluate potential claims and interests of relevant stakeholders: patients as data subjects in the public healthcare system, for-profit companies, the public, and physicians and their healthcare institutions. Finally, we address the tensions between legitimate claims of different stakeholders in order to suggest conditions that might ensure ethically sound ReuseForPro.
resultsWe conclude that there are good reasons to grant for-profit companies access to medical data if they meet certain conditions: among others they need to respect patients' informational rights and their actions need to be compatible with the public's interest in health benefit from ReuseForPro.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.